These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 29999484)

  • 41. A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma.
    Steffanoni S; Calimeri T; Anzalone N; Mastaglio S; Bernardi M; Ferreri AJ
    Expert Rev Hematol; 2022 Jan; 15(1):33-43. PubMed ID: 34904506
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.
    Chamberlain MC; Johnston SK
    Neuro Oncol; 2010 Jul; 12(7):736-44. PubMed ID: 20511181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
    Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Risk - adapted intensive induction therapy, autologous stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell lymphoma].
    Vorobyev VI; Gemdzhian EG; Dubrovin EI; Nesterova ES; Kaplanov KD; Volodicheva EM; Zherebtsova VA; Kravchenko SK
    Ter Arkh; 2019 Jul; 91(7):41-51. PubMed ID: 32598735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
    Puckrin R; Chua N; Shafey M; Stewart DA
    Leuk Lymphoma; 2022 Oct; 63(10):2444-2452. PubMed ID: 35459424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
    Fang Y; Su N; Ma S; Cai J; Zhong L; Li W; Huang H; Li Z; Huang H; Xia Y; Liu P; Guo L; Li Z; Wu Y; Tian X; Wang J; Zhang Y; Cai Q
    Ann Hematol; 2022 Mar; 101(3):595-605. PubMed ID: 34985557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
    Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
    Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
    Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
    Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Challenges and opportunities in primary CNS lymphoma: A systematic review.
    Kerbauy MN; Moraes FY; Lok BH; Ma J; Kerbauy LN; Spratt DE; Santos FP; Perini GF; Berlin A; Chung C; Hamerschlak N; Yahalom J
    Radiother Oncol; 2017 Mar; 122(3):352-361. PubMed ID: 28104300
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
    Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
    Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
    Nagane M
    Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
    Wight JC; Yue M; Keane C; Johnston A; Linton K; Chin C; Wai SH; Talaulikar D; Gasiorowski R; Cheah CY; Gregory GP; Dickinson M; Minson A; Coombes C; Ku M; Lam S; Hawkes EA
    Br J Haematol; 2019 Oct; 187(2):174-184. PubMed ID: 31236941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study.
    Kiefer T; Hirt C; Späth C; Schüler F; Al-Ali HK; Wolf HH; Herbst R; Maschmeyer G; Helke K; Kessler C; Niederwieser D; Busemann C; Schroeder H; Vogelgesang S; Kirsch M; Montemurro M; Krüger WH; Dölken G;
    Ann Oncol; 2012 Jul; 23(7):1809-12. PubMed ID: 22115927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
    Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
    J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.
    Ferreri AJ; Donadoni G; Cabras MG; Patti C; Mian M; Zambello R; Tarella C; Di Nicola M; D'Arco AM; Doa G; Bruno-Ventre M; Assanelli A; Foppoli M; Citterio G; Fanni A; Mulè A; Caligaris-Cappio F; Ciceri F
    J Clin Oncol; 2015 Nov; 33(33):3903-10. PubMed ID: 26282634
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.
    Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A
    J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Management of primary central nervous system lymphoma].
    Gonzalez-Aguilar A; Houillier C; Soussain C; Hoang-Xuan K
    Rev Neurol (Paris); 2011 Oct; 167(10):721-8. PubMed ID: 21906768
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How we treat primary central nervous system lymphoma.
    Calimeri T; Steffanoni S; Gagliardi F; Chiara A; Ferreri AJM
    ESMO Open; 2021 Aug; 6(4):100213. PubMed ID: 34271311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.